Navigation Links
China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Date:8/19/2007

-- Revenues increase 28% to $8.9 Million for Q2 of 2007 versus $7 Million

for Q2 of 2006 -- Gross profit increases 18% to $2.2 Million for Q2 of 2007 versus $1.9

Million for Q2 of 2006 -- Announces LOI to Restructure $11.5 Million of Debt to Equity and Acquire

Remaining 49% of Erye

BEIJING, Aug. 15 /Xinhua-PRNewswire-FirstCall/ -- China Biopharmaceuticals Holdings, Inc. (OTC Bulletin Board: CHBP), a leading Chinese pharmaceutical company focused on the development, manufacturing and marketing of innovative drugs in China, today announced its results for the second quarter ended June 30, 2007.

Revenue for the three months ended June 30, 2007 increased 28% to $8.9 million compared to $7 million for the period ended June 30, 2006. The increase in revenues was mainly attributable to the 31% revenue growth of the Company's subsidiary Erye Pharmaceutical Limited Company ("Erye"). Additionally, the Company realized a full quarter of revenue this year from Enshi as opposed to last year when the acquisition of Enshi was made.

Recent industry developments in China have provided Erye a great opportunity to continue to grow its core business going forward. The Chinese government has invested billions of dollars in a new insurance policy called "Cooperative Medicare." This policy is aimed at providing insurance for farmers in China. Erye will provide their products, which are currently focused on middle-end to low-end markets, to these farmers under the new policy.

Cost of goods sold increased 31% to $6.7 million for the second quarter of 2007 compared to $5.1 million for the second quarter of 2006. Cost of goods sold as a percentage of sales revenues was approximately 75% for the three months ended June 30, 2007 compared to 74% for the three months ended June 30, 2006. The increase in cost of goods sold has remained consistent with the growth of sales for th22

Email: alan.sheinwald@HCInternational.com

e quarter.

Gross profit increased 18% for the three months ended June 30, 2007 to $2.2 million compared to $1.9 million for the same period in 2006. The gross profit margin for the three months ended June 30, 2007 was 25% compared to 27% for the same period in 2006.

Income from operations for the three months ended June 30, 2007 decreased 25% to $649 thousand compared to $860 thousand for the same period in 2006. The decrease is mainly attributable to high operational expenses and poor operational performance of Enshi of which financials were only partially reflected for the three months ended June 30, 2006.

The Company reported a net loss for the second quarter of 2007 of $29 thousand compared to a net income of $391 thousand for the second quarter of 2006. The net loss for the quarter was mainly attributable to the higher payment and accrued interest expenses as a result of the acquisition financing loan due to RimAsia Capital Partners for Enshi. EBITDA for the second quarter of 2007 decreased 25% to $945 thousand compared to $1.2 million for the same period in 2006.

As of June 30, 2007, total assets were $50 million and total liabilities were $36.7 million. Shareholder equity was $13.4 million or $.37 per share.

Ms. ZHANG Jian, Chairwoman of the Board, commented, "This quarter the management team and I have been focused on restructuring our balance sheet and building our core business, especially our most successful subsidiary, Erye. Recently, we signed a letter of intent with RimAsia to convert their $11.5 million of debt to equity. I can assure our shareholders that we are working diligently to ensure these negotiations become finalized in a timely fashion."

Ms. ZHANG Jian, continued, "I am also pleased to announce our intent to acquire the remaining 49% of Erye. With the continued success of Erye this quarter and the strong growth potential of this subsidiary, the team and I are eager to finalize the acquisition of the remaining equity. Once completed, I look forward to updating everyone on the signing of both of these definitive agreements and provide more guidance on our plans for the future."

Subsequent Events

Subsequent to the end of our second quarter on August 2, 2007, the Company and RimAsia Capital Partners ("RACP") entered into a letter of intent to restructure their $11.5 million loan. If executed as drafted, the Company must first acquire the 49% minority interest in Erye, so that Erye becomes wholly owned by the Company. The Company will also authorize a new class of preferred stock. At that time, Rim Asia will convert the $11.5 million loan into a senior redeemable convertible preferred stock with a conversion price of $1.02. Additionally, the Company will reduce the exercise price on the warrants issued with the original $11.5 million loan, from $1.375 to $1.26 and the term of the warrants will be extended from 3 years to 4.5 years from the date of the conversion of the principal of the loan into preferred stock.

Erye has demonstrated an impressive growth of more than 38% in net income in the first half of 2007. The Enshi acquisition has slowed down our original expansion plans due to management resources being devoted to its operations and integration. However, we still believe in the overall strategy of growth through organic opportunities and acquisitions. We expect that the recent changes in our management, with the addition of Erye's top management, Ms. ZHANG Jian and Mr. SHI Mingsheng will improve our overall operations. They recently joined our board of directors and are now playing an active role in our management, giving play to their industrial and manufacturing and marketing expertise.

About China Biopharmaceuticals Holdings, Inc.

China Biopharmaceuticals Holdings, Inc. (OTC Bulletin Board: CHBP) is a vertically integrated pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of small and large molecule pharmaceutical products, including medicines, vaccines, and active pharmaceutical ingredients for various categories of diseases. CHBP's product portfolio includes 260 drugs already approved for manufacturing and marketing by the Chinese State Food and Drug Administration (SFDA). CHBP also has submitted 15 drug applications to the SFDA for its review during the calendar year of 2006. CHBP is a U.S.-listed public company with operating subsidiaries and senior management based in China. For further information, please visit our website at http://www.cbioinc.com .

Safe Harbor Statement

The statements contained herein that are not historical facts are "forward-looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward-looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

CONSOLIDATED BALANCE SHEET

AS OF JUNE 30, 2007

June 30,

2007

------------

CURRENT ASSETS: Unaudited

------------

Cash $ 1,230,258

Accounts receivable, trade, net of

allowance for doubtful accounts of $934,516 6,860,309

Accounts receivable, related parties 259,347

Other receivables 2,614,674

Other receivables - related parties 3,123,894

Advances to suppliers 244,161

Prepaid expenses 48,257

Inventories 7,605,936

Loan to shareholders 42,794

------------

Total current assets 22,029,630

------------

PLANT AND EQUIPMENT, net 12,278,966

------------

OTHER ASSETS:

Intangible asset, net 12,702,943

Long term notes receivable 657,797

Long term other receivables - related parties 554,344

Restricted cash 840,285

Other assets 989,624

------------

Total other assets 15,744,993

------------

Total assets $ 50,053,589

============

CURRENT LIABILITIES:

Accounts payable $ 5,427,225

Short-term loans 5,588,750

Long term debt - current maturities 11,500,000

Other payables 104,896

Other payables - related parties 1,514,292

Customer deposits 1,845,349

Notes payable 2,406,450

Taxes payable 1,308,375

Other accrued liabilities 1,403,995

------------

Total current liabilities 31,099,332

------------

LONG TERM LIABILITIES:

Other long term liabilities 164,848

------------

Total liabilities 31,264,180

------------

COMMITMENTS AND CONTINGENCIES --

------------

MINORITY INTEREST 5,420,442

------------

SHAREHOLDERS' EQUITY:

Preferred stock, $0.01 par value, 10,000,000

shares authorized; 417,500 shares

Issued and outstanding 4,175

Common stock, $0.01 par value, 200,000,000 shares authorized;

36,465,312 shares issued and outstanding 364,654

Paid-in capital 13,093,750

Capital receivable (252,471)

Deferred compensation (46,125)

Statutory reserves 2,754,547

Retained earnings (deficit) (3,771,410)

Accumulated other comprehensive income 1,221,847

------------

Total shareholders' equity 13,368,967

------------

Total liabilities and shareholders' equity $ 50,053,589

============

CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME

FOR THE THREE MONTHS ENDED JUNE 30, 2007 AND 2006

Three months ended June 30,

2007 2006

------------ ------------

(Unaudited) (Unaudited)

------------ ------------

Restated

------------

REVENUES $ 8,891,559 $ 6,965,818

COST OF GOODS SOLD 6,656,183 5,077,169

------------ ------------

GROSS PROFIT 2,235,376 1,888,649

------------ ------------

OPERATING EXPENSES

Research and development 66,748 240,747

Selling, general and

administrative 1,519,246 788,133

------------ ------------

Total Operating

Expenses 1,585,994 1,028,880

------------ ------------

INCOME FROM OPERATIONS 649,382 859,769

------------ ------------

OTHER INCOME (EXPENSE)

Interest income (expense),

net (314,481) (138,091)

Other income (expense),

net 217,597 195,139

------------ ------------

Total Other Income

(expense), net (96,884) 57,048

------------ ------------

INCOME BEFORE INCOME TAXES

AND MINORITY INTEREST 552,498 916,817

PROVISION FOR INCOME TAXES 16,015 59,530

------------ ------------

INCOME BEFORE MINORITY

INTEREST 536,483 857,287

MINORITY INTEREST 565,772 412,970

------------ ------------

INCOME (LOSS) FROM

CONTINUING OPERATIONS (29,289) 444,317

LOSS FROM DISCONTINUED

OPERATIONS, net of tax -- (53,717)

------------ ------------

NET (LOSS) INCOME (29,289) 390,600

OTHER COMPREHENSIVE

INCOME:

Foreign currency

translation adjustment 319,364 394,168

------------ ------------

COMPREHENSIVE (LOSS)

INCOME $ 290,075 $ 784,768

============ ============

INCOME (LOSS) PER

SHARE OF COMMON STOCK

BASIC

CONTINUING

OPERATIONS $ (0.001) $ 0.013

DISCONTINUED

OPERATIONS -- (0.002)

------------ ------------

Total-Basic $ (0.001) $ 0.011

============ ============

DILUTED

CONTINUING

OPERATIONS $ (0.001) $ 0.013

DISCONTINUED

OPERATIONS -- (0.002)

------------ ------------

Total-diluted $ (0.001) $ 0.011

============ ============

WEIGHTED AVERAGED NUMBER

OF SHARES OUTSTANDING

- BASIC 36,402,125 33,662,770

============ ============

WEIGHTED AVERAGED NUMBER

OF SHARES OUTSTANDING

- DILUTED 36,819,625 34,592,770

============ ============

For more information, please contact:

HCI Emerging Growth

Alan Sheinwald, Partner

Tel: +1-914-669-02
'/>"/>

SOURCE China Biopharmaceuticals Holdings, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. How do you level the playing field with China?
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
Breaking Biology Technology:
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
Breaking Biology News(10 mins):